TY - JOUR T1 - Insufficient evidence exists to evaluate effects of blood transfusions and iron therapy for treatment of anaemia in patients with heart disease—erythropoietin agonists do not improve outcomes JF - Evidence Based Medicine JO - Evid Based Med SP - 139 LP - 139 DO - 10.1136/eb-2014-101719 VL - 19 IS - 4 AU - Rohan Samson AU - Thierry Le Jemtel Y1 - 2014/08/01 UR - http://ebm.bmj.com/content/19/4/139.abstract N2 - Commentary on: Kansagara D, Dyer E, Englander H, et al. Treatment of anemia in patients with heart disease: a systematic review. Ann Intern Med 2013;159:746–57.OpenUrlCrossRefPubMedWeb of Science The prevalence of anaemia ranges from 20% to 40% in patients with coronary heart disease (CHD) and is nearly 50% in patients with chronic heart failure (CHF). Anaemia is an independent predictor of poor clinical outcomes in patients with heart disease.1 ,2 Targeting anaemia to improve clinical outcomes is therefore a logical inference, with recent interest being largely driven by trials evaluating erythropoietin stimulating agents (ESAs) and one trial of intravenous iron therapy in CHF. Although recently reported Reduction of Events with Darbepoetin Alfa in Heart Failure (RED-HF) trial demonstrated no benefit of darbepoetin in CHF,3 clinical equipoise exists with … ER -